Key result
Black race is linked to ~17% higher odds of non-optimal anticoagulation therapy in AF.
Why the study?
Studies continue to document underuse of anticoagulation therapy in minority populations and women, prompting evaluation of non-optimal anticoagulation by race and sex using a decision support tool.
Are Black race and female sex associated with a higher likelihood of receiving non-optimal anticoagulation therapy as determined by an individualized decision support tool in patients with non-valvular atrial fibrillation?
Cohort (n=14,942)
No
Are Black race and female sex associated with a higher likelihood of receiving non-optimal anticoagulation therapy as determined by an individualized decision support tool in patients with non-valvular atrial fibrillation?
Black patients and women with atrial fibrillation have significantly higher odds of receiving non-optimal anticoagulation therapy and stand to gain more quality-adjusted life years if treatment is optimized.
Answers are grounded in this paper and cite their sources.
May indicate inequities in AF anticoagulation; extends observational data but leaves open effects of targeted interventions.
Atrial fibrillation (AF) is the most common cardiac rhythm disorder, responsible for 15 % of strokes in the United States. Studies continue to document underuse of anticoagulation therapy in minority populations and women. Our objective was to compare the proportion of AF patients by race and sex who were receiving non-optimal anticoagulation as determined by an Atrial Fibrillation Decision Support Tool (AFDST). Retrospective cohort study including 14,942 patients within University of Cincinnati Health Care system. Data were analyzed between November 18, 2020, and November 20, 2021. Discordance between current therapy and that recommended by the AFDST. In our two-category analysis 6107 (41 %) received non-optimal anticoagulation therapy, defined as current treatment category ≠ AFDST-recommended treatment category. Non-optimal therapy was highest in Black (42 % [n = 712]) and women (42 % [n = 2668]) and lower in White (39 % [n = 4748]) and male (40 % [n = 3439]) patients. Compared with White patients, unadjusted and adjusted odds ratios of receiving non-optimal anticoagulant therapy for Black patients were 1.13; 95 % CI, 1.02–1.30, p = 0.02; and 1.17; 95%CI, 1.04–1.31, p = 0.01; respectively, and 1.10; 95 % CI 1.03–1.18, p = 0.005; and 1.36; 95 % CI, 1.25–1.47, p < 0.001; for females compared with males. In patients with atrial fibrillation in the University of Cincinnati Health system, Black race and female sex were independently associated with an increased odds of receiving non-optimal anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Eckman et al. (2022) conducted a cohort in Non-valvular atrial fibrillation or atrial flutter (n=14,942). Black race and female sex vs. White race and male sex was evaluated on Receiving non-optimal anticoagulation therapy (current treatment category discordant with Atrial Fibrillation Decision Support Tool [AFDST] recommendation with a minimum clinically significant gain threshold of ≥0.1 QALYs) (Adjusted OR 1.17 (Black vs White); Adjusted OR 1.36 (Female vs Male), 95% CI 1.04-1.31, p=0.01). Black race and female sex were independently associated with increased odds of receiving non-optimal anticoagulation therapy in AF.
Synapse has enriched 10 related papers. Consider them for comparative context: